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Afatinib, a second-generation epidermal growth factor 
receptor-tyrosine kinase inhibitor (EGFR-TKI), prolonged 
survival in EGFR-mutated non-small cell lung cancer (NSCLC) 
patients [1]. Due to the increase in the incidence of lung 
cancer among elderly individuals, the efficacy and safety 
of EGFR-TKIs for the treatment of elderly patients with 
non-small-cell lung cancer (NSCLC) have become interested. 
Aging is associated with a higher prevalence of comorbid 
disease. Most patients at the time of diagnosis of NSCLC 
have suffered some types of comorbidities such as chronic 
kidney disease (CKD), contraindicating any chemotherapy. 
Afatinib has some dosage forms so that it can be reduced, 
and afatinib and its metabolites are not excreted 
predominantly via the urine [2]. Successful afatinib 
treatment of advanced NSCLC patients undergoing 
hemodialysis have already reported [3, 4]. In this report, 
we present a successfully treatment of an advanced NSCLC 
patient, who was unsuitable for chemotherapy because of 
CKD, start with afatinib at the dose of 20 mg/day. 
A 79-year-old woman, never smoker, was diagnosed with 
stage IIIB lung adenocarcinoma. Eastern Cooperative 
Oncology Group (ECOG) performance status (PS) was 1. She 
underwent a right superior lung lobectomy plus mediastinal 
lymph nodes dissection. An EGFR exon 21 L858R was 
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identified in the resected tumor. Six months after surgery, 
she developed pulmonary metastases. In the meanwhile, she 
had CKD (serum creatinine level 1.18 mg/dl, blood urea 
nitrogen level 28 mg/dl, and creatinine clearance (CC) 34 
ml/min according to the Cockroft and gault formula. She 
started afatinib (20mg a day). Renal function was checked 
twice monthly, with CC ranging between 32 and 48 ml/min 
(serum creatinine levels between 0.86 and 1.43 mg/dl). 
Nineteen months after the initiation of afatinib therapy, 
the patient is still well on treatment, achieving partial 
response.  
     In our patient, the choice of EGFR-TKI was based on 
the need for palliative treatment. Afatinib has tablets 
that can be reduced in several stages. The starting dose of 
afatinib was 20 mg a day, supposing that if side effects 
appeared it would be further reduced. However, further 
renal function was not impaired by afatinib therapy, and no 
other severe toxicity was developed. Afatinib and its 
metabolites are excreted predominantly via the feces, with 
urinary excretion representing a minor elimination pathway 
(4.29%)[2]. To the best of our knowledge, this is the first 
report in which erlotinib was administered in elderly 
patients with CKD achieving disease control. EGFR-TKI is 
the cornerstone for the treatment of advanced EGFR-mutated 
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NSCLC patients. However, its utility on patients with CKD 
has largely been unstudied, because most cancer drug trials 
exclude such patients. Afatinib can become one treatment 
option for patients with NSCLC and CKD.  
 
 
Disclosure of interest 
The authors declare that there is no conflicts of interest 
concerning this article. 
 
  
5 
 
References 
1. Keating GM. Afatinib: A Review in Advanced Non-Small 
Cell Lung Cancer. Target Oncol 2016; 11: 825-35. 
2. Stopfer P, Marzin K, Narjes H, et al. Afatinib 
pharmacokinetics and metabolism after oral administration 
to healthy male volunteers. Cancer Chemother Pharmacol 
2012; 69: 1051-61. 
3. Bersanelli M, Tiseo M, Artioli F, Lucchi L, Ardizzoni A. 
Gefitinib and afatinib treatment in an advanced non-small 
cell lung cancer (NSCLC) patient undergoing hemodialysis. 
Anticancer Res 2014; 34: 3185-8. 
4. Imai H, Kaira K, Naruse I, et al. Successful afatinib 
treatment of advanced non-small-cell lung cancer patients 
undergoing hemodialysis. Cancer Chemother Pharmacol 2017; 
79: 209-13. 
